For information about current and pending clinical studies, or to refer one of your patients for consideration, please contact Metropolitan Animal Specialty Hospital’s Oncology Department at (855)-350-PETS (7387). A member of out oncology team would be pleased to discuss whether an available study would benefit your patient.

Current Clinical Studies

Study to Determine the Safety and Efficacy of TANOVEATM (Rabacfosadine for Injection) in Cats with Lymphoma, Leukemia, and Myeloma, Using a Dose Escalation Model

Patients Being Recruited: Cats with lymphocytic or lymphoblastic lymphoma, lymphoid leukemia, multiple myeloma or plasma cell tumor

Goal of Study:

  • Determine the safety of TANOVEA-CATM in cats
  • Establish dosing of the drug in cats
  • Evaluate efficacy of the drug for cats with lymphoma, leukemia and myeloma-related disorders in cats

Inclusion Criteria:

  • Cats must be > 1 year of age, and FIV/FeLV negative
  • Cytologic or histologic diagnosis of lymphoma, leukemia or myeloma-related disorder
  • Adequate organ function
  • Appropriate washout from previous chemotherapy or radiation therapy
  • No significant concurrent disease as determined by investigator

Study Protocol:

  • Additional eligibility testing may be done prior to enrollment
  • TANOVEA-CATM will be administered intravenously every 3 weeks for up to 5 treatments (or 2 treatment past complete remission)
  • Bloodwork will be done 1 week after the 1st treatment
  • Monthly rechecks will be required following study completion
  • There is no placebo group (all cats will receive study drug)

Financial Incentives:

  • TANOVEA-CATM is provided at no cost
  • Participants will receive $1500 towards the cost of treatment
  • The study will pay up to $3000 to cover hospitalization related to adverse events (should they occur)

Please contact Dr. Jennifer Pierro (DACVIM – oncology) at MASH if you have a patient that may be a candidate for this study (or if you have any questions about oncologic cases). 855-350-PETS onco@mash.vet